Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| BLSM | 424B4 | neutral | 6/10 | BlossomHill Therapeutics priced its IPO of 9,375,000 shares at $16.00 per share, raising $150 million in gross proceeds | Aug 7, 2026 |
| NEOG | 8-K | neutral | 2/10 | Director Thierry Bernard resigned from Neogen's board on August 3, 2026. The filing provides no reason, no replacement, | Aug 7, 2026 |
| AMGN | CLUSTER | neutral | 2/10 | Two Amgen senior executives (SVP & CCO Nancy Grygiel and SVP of HR Derek Miller) executed open-market sales totaling app | Aug 7, 2026 |
| ATYR | 8-K | bearish | 7/10 | aTyr Pharma reported Q2 2026 results alongside a major corporate restructuring: a ~60% workforce reduction, CFO and GC d | Aug 7, 2026 |
| VNRX | 8-K | bearish | 6/10 | VolitionRx issued an aggregate of 779,371 shares to Lind Global Asset Management XII LLC between July 14 and August 6, 2 | Aug 7, 2026 |
| MANE | S-1 | bearish | 7/10 | Veradermics filed an S-1 registration statement for the resale of up to 17,072,058 shares of common stock (including 300 | Aug 7, 2026 |
| CELU | 8-K | bearish | 5/10 | Celularity Inc. terminated Rick Gonzalez, its Chief Commercial Officer, effective August 5, 2026. No replacement was nam | Aug 7, 2026 |
| TRAX | 3/A | neutral | 2/10 | Daniel Faga, President and CEO of First Tracks Biotherapeutics, filed this 3/A on August 7, 2026 to amend his initial be | Aug 7, 2026 |
| PGEN | CLUSTER | neutral | 2/10 | CFO Thomasian sold 100K shares ($606K) and COO Shah sold 32.7K shares ($225K) in the past week, totaling $831K. This rep | Aug 7, 2026 |
| JNJ | CLUSTER | neutral | 3/10 | JNJ CEO Joaquin Duato and EVP/Chief Legal Officer Elizabeth Forminard executed ~$16.6M in open-market sales over two day | Aug 7, 2026 |
| ACAD | CLUSTER | neutral | 2/10 | Two ACAD insiders (CFO and EVP R&D) sold a combined $601K in open-market transactions over a 7-day window. The total rep | Aug 7, 2026 |
| ENTX | PRESS-RELEASE | mixed | 6/10 | Entera Bio reported Q2 2026 EPS of $-0.14, a 75% miss versus the $-0.08 consensus, though the company highlighted FDA al | Aug 7, 2026 |
| PULM | S-3/A | bearish | 5/10 | Pulmatrix filed Amendment No. 1 to its S-3 shelf registration to register the resale of up to 490,910 shares of common s | Aug 7, 2026 |
| SRZN | 25-NSE | neutral | 3/10 | Nasdaq filed a Form 25-NSE on August 7, 2026 to remove from listing and registration the Warrants expiring 8/10/2026 of | Aug 7, 2026 |
| AGEN | S-3 | bearish | 7/10 | Agenus filed a resale registration statement on Form S-3 to register up to 77,976,718 shares of common stock held by sel | Aug 7, 2026 |
| ATTO | CLUSTER | bullish | 7/10 | Two major 10% owners, Frazier Life Sciences and Sanofi, made open-market purchases totaling $15.1M at $17/share on Augus | Aug 7, 2026 |
| ISPC | 8-K | bearish | 7/10 | iSpecimen (ISPC) closed a $5M public offering on August 7, 2026, issuing 996,231 shares of common stock and pre-funded w | Aug 7, 2026 |
| INCY | CLUSTER | neutral | 2/10 | Two senior R&D executives at Incyte (President and Chief Scientific Officer) sold a combined $2.18M of stock in the week | Aug 7, 2026 |
| ANNX | INST-CLUSTER | mixed | 4/10 | Four institutional investors added $19.7M in net new positions in ANNX during 2026-Q2, led by a massive State Street bui | Aug 7, 2026 |
| MANE | INST-CLUSTER | bullish | 6/10 | Six institutional investors, primarily active asset managers, accumulated $207.5M in new Veradermics (MANE) positions du | Aug 7, 2026 |
| MAZE | INST-CLUSTER | bullish | 5/10 | Eight institutional investors added or doubled positions in Maze Therapeutics during 2026-Q2, with aggregate buying of $ | Aug 7, 2026 |
| ACHV | INST-CLUSTER | bullish | 4/10 | Three institutional investors (State Street, Citigroup, Russell Investments) all doubled their ACHV positions in Q2 2026 | Aug 7, 2026 |
| TWST | 144 | neutral | 3/10 | Director Robert Chess filed a Form 144 notice to sell 18,417 shares of Twist Bioscience common stock, valued at approxim | Aug 7, 2026 |
| AZN | COURT-RULING | neutral | 3/10 | The Delaware Court of Chancery resolved final judgment interest calculations in a post-merger indemnification dispute be | Aug 7, 2026 |
| SILO | EFFECT | neutral | 4/10 | Silo Pharma's S-3 shelf registration statement became effective on August 6, 2026, allowing the company to sell securiti | Aug 7, 2026 |
| NRXP | 8-K | bullish | 6/10 | NRx Pharmaceuticals disclosed that the FDA completed first-round review of its ANDA for preservative-free ketamine with | Aug 7, 2026 |
| ANIP | 8-K | bullish | 6/10 | ANI Pharmaceuticals reported record Q2 2026 revenue of $266.0M (+25.9% YoY), beating consensus of $260.1M. Adjusted non- | Aug 7, 2026 |
| KPRX | 8-K | neutral | 4/10 | Kiora Pharmaceuticals reported Q2 2026 net loss of $2.1M ($0.34 per share), improved from $2.2M ($0.54) in Q2 2025, with | Aug 7, 2026 |
| PPBT | 6-K | neutral | 4/10 | Purple Biotech reported Q2 2026 financial results with a net income of $0.4M driven by non-cash warrant revaluation gain | Aug 7, 2026 |
| NERV | 8-K | neutral | 4/10 | Minerva Neurosciences reported Q2 2026 financial results with a GAAP net income of $17.5M driven by a non-cash warrant l | Aug 7, 2026 |